Blueprint Medicines Corp (NASDAQ:BPMC) has a beta value of 0.84 and has seen 28.28 million shares traded in the recent trading session. The company, currently valued at $8.26B, closed the recent trade at $127.96 per share which meant it gained $26.61 on the day or 26.25% during that session. The BPMC stock price is 4.74% off its 52-week high price of $121.90 and 42.92% above the 52-week low of $73.04. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.71 million shares traded. The 3-month trading volume is 991.09K shares.
The consensus among analysts is that Blueprint Medicines Corp (BPMC) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 10 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.
Blueprint Medicines Corp (NASDAQ:BPMC) trade information
Over the past 30 days, the shares of Blueprint Medicines Corp (NASDAQ:BPMC) have changed 28.92%. Short interest in the company has seen 5.67 million shares shorted with days to cover at 6.38.
Wall Street analysts have a consensus price target for the stock at $150, which means that the shares’ value could jump 14.69% from the levels at last check today.. The projected low price target is $150.0 while the price target rests at a high of $150.0. In that case, then, we find that the latest price level in today’s session is -17.22% off the targeted high while a plunge would see the stock gain -17.22% from the levels at last check today..
Blueprint Medicines Corp (BPMC) estimates and forecasts
The company’s shares have gained 35.22% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 31.87% over the past 5 years.
BPMC Dividends
Blueprint Medicines Corp is expected to release its next earnings report on 2025-Apr-30 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Blueprint Medicines Corp (NASDAQ:BPMC)’s Major holders
Insiders own 0.87% of the company shares, while shares held by institutions stand at 109.34% with a share float percentage of 110.30%. Investors are also buoyed by the number of investors in a company, with Blueprint Medicines Corp having a total of 489.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 6.65 million shares worth more than $716.45 million. As of 2024-06-30, BLACKROCK INC. held 10.5758% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.54 million shares as of 2024-06-30. The firm’s total holdings are worth over $704.72 million and represent 10.4026% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price New Horizons Fund, Inc. . As of Mar 31, 2025 , the former fund manager holds about 3.11% shares in the company for having 2.01 shares of worth $257.1 million while later fund manager owns 2.0 shares of worth $255.57 million as of Mar 31, 2025 , which makes it owner of about 3.09% of company’s outstanding stock.
